Randomized Comparison of Vonoprazan–Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapies for <scp> <i>Helicobacter pylori</i> </scp> Eradication: A Multicenter Trial Evaluating National Centralized Drug Procurement Antibiotics

This study confirms that 10-day vonoprazan-amoxicillin dual therapy (using National Centralized Drug Procurement antibiotics) demonstrates noninferior efficacy to bismuth quadruple therapy while offering superior safety, better compliance, and the advantage of shorter treatment duration. These findings support its adoption as a first-line regimen for large-scale H. pylori eradication programs.